Non-coding RNAs as drug targets

By Masayuki Matsui, D. Corey. Nature reviews. Drug discovery, 2016

904 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Noncoding RNA (ncRNA) is an RNA molecule that is not translated into a protein, but affects normal gene expression and disease progression, including microRNA, intronic RNA, repetitive RNA, and long ncRNA.(102) LncRNAs function as competing endogenous RNAs (ceRNAs) by competitively occupying shared ”
Non-coding RNAs in disease: from mechanisms to therapeutics (2023, positive): “…recent reviews have extensively discussed a range of approaches to modulate the therapeutic potential of ncRNAs, including the use of small interfering RNAs (siRNAs), ASOs, shRNAs, anti-miRNAs, miRNA mimics, miRNA sponges, therapeutic circRNAs and CRISPR–Cas9-based gene editing 53,105,275–278 .”